Introduction: To evaluate the association between the first 5-item version of the International Index of Erectile Function (IIEF-5) and Erection Hardness Grading Scale (EHGS) scores in patients who received sildenafil citrate treatment due to erectile dysfunction (ED). Patients and Methods: A total of 81 men with ED lasting for 6 months or longer were included in this study. Mean age was 51 years (range 21–75). All patients were given 50 mg sildenafil citrate (Viagra®) 4 times a week during an 8-week period and they were asked to attempt sexual intercourse when they used the drug. Results: The mean pretreatment IIEF-5 and EHGS scores were 6.7 ± 2.5 and 1.7 ± 0.5, respectively. These values were 15.3 ± 5.1 and 2.8 ± 0.6 after the treatment, respectively. There were statistically significant differences in all scores between before and after treatment for IIEF-5 and EHGS scores (p < 0.001). We found a very strong association between IIEF-5 and EHGS scores in the pretreatment period (gamma = 0.916, p < 0.001). However, there was a fair agreement between IIEF-5 and EHGS scores (kappa coefficient: 0.375). Conclusions: Our experience showed that there was no significant agreement between the IIEF-5 and EHGS scores in patients treated with sildenafil citrate.

Keywords:
International Index of Erectile Function, Sildenafil treatment, Erectile dysfunction, Erection hardness
This content is only available via PDF.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.